As of the approval, the treatment is expected to be available to patients in the coming weeks. More: Adakveo bags FDA approval for sickle cell pain Source: News
read moreThe trial is the first with an SGLT2 inhibitor investigating the treatment of heart failure in patients with reduced ejection fraction, with and without type II diabetes. More: Farxiga demonstrates consistent heart failure benefits in late-stage trial Source: News
read moreThe industry body hopes that the proceeding Government will “shape one of our country’s most valuable assets: an incredible pharmaceutical industry that employs tens of thousands and invests billions in research.” More: ABPI launches general election manifesto Source: News
read moreIsturisa, Mayzent and Polivy were among the recommendations. More: CHMP backs seven meds in November meeting Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals